Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Investigation of the molecular mechanisms of the synergy between erdafitinib and quisinostat

ABSTRACT: Investigation of the molecular mechanisms of the synergy between erdafitinib and quisinostat

PROVIDER: PRJNA887105 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21803780_1.fastq.gz	Fastqsanger.gz
	SRR21803780_2.fastq.gz	Fastqsanger.gz
	SRR21803781_1.fastq.gz	Fastqsanger.gz
	SRR21803781_2.fastq.gz	Fastqsanger.gz
	SRR21803782_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Investigation of the molecular mechanisms of the synergy between erdafitinib and quisinostat

Project description:We first verified that erdafitinib is synergistic with quisinostat in vitro and confirmed that the combinational treatment can significantly enhance the inhibition of tumor growth and prolong the survival in vivo for bladder cancers with FGFR3 fusions. Next, in order to understand the underlying molecular mechanisms of this synergy, we performed RNA-seq analysis. We revealed that quisinostat can concomitantly inhibit FGFR signaling with erdafitinib by suppressing the translation of FGFR3 fusions. In addition, quisinostat can also sensitize bladder cancer cells to erdafitinib by downregulating HDGF, which is a second mechanism of the synergy independent of FGFR signaling.

2022-10-11 | GSE214814 | GEO

Specificity, synergy, and mechanisms of splice-modifying drugs

Project description:Specificity, synergy, and mechanisms of splice-modifying drugs

| PRJNA916518 | ENA

Investigation of molecular mechanisms of iron dependency alteration of ANKL by enviromental factors

Project description:Investigation of molecular mechanisms of iron dependency alteration of ANKL by enviromental factors

| PRJNA1033594 | ENA

Investigation of the molecular mechanisms underlying of herb pair Daji and Gancao with different combination designs acting on hepatocellular carcinoma ascites mice

Project description:The differentially expressed genes among the blank control, ascites mouse model, Daji (DJ)/ Gancao (GC)-synergistic treatment and DJ/GC-antagonistic treatment groups were identified to investigate the molecular mechanisms underlying the herb pair DJ and GC acting on ascites mice. In the study, 50 male Kunming mice were randomly divided into 5 groups, namely, normal control group, model group, Daji/Gancao-synergy group, Daji/Gancao-antagonism group, Daji group. Normal control group and model group were intragastrically administrated with normal saline, while other 3 groups were intragastrically administrated with corresponding doses.

2016-01-20 | E-GEOD-76818 | biostudies-arrayexpress

Transcriptome sequencing facilitates reveal molecular mechanisms between GSK2 and WRKY53

Project description:Transcriptome sequencing facilitates reveal molecular mechanisms between GSK2 and WRKY53

| PRJNA623220 | ENA

Specificity, synergy, and mechanisms of splice-modifying drugs

Project description:Drugs that target pre-mRNA splicing hold great therapeutic potential, but the mechanistic understanding of how these drugs function is limited. Here we introduce a biophysical modeling framework that can quantitatively describe the sequence-specific and concentration-dependent behavior of splice-modifying drugs. Using massively parallel splicing assays, RNA-seq experiments, and precision dose-response curves, we apply this framework to two drugs, risdiplam and branaplam, developed for treating spinal muscular atrophy. The results quantitatively define the specificities of risdiplam and branaplam for 5’ splice site sequences, suggest that branaplam recognizes 5’ splice sites via two distinct interaction modes, and disprove the prevailing two-site hypothesis for risdiplam activity at SMN2 exon 7. The results also show, more generally, that single-drug cooperativity and multi-drug synergy are widespread among splice-modifying drugs. Our biophysical modeling approach thus clarifies the mechanisms of existing splice-modifying treatments and provides a quantitative basis for the rational development of new therapies.

2023-01-09 | GSE221868 | GEO

Mechanism of antimicrobial synergy between doxycycline and carprofen against methicillin-resistant Staphylococus pseudintermedius

Project description:We previously showed that doxycycline and carprofen , a veterinary non-steroidal anti-inflammatory drug, have synergistic antimicrobial activity against methicillin-resistant Staphylococus pseudintermedius (MRSP) carrying the tetracycline resistance determinant TetK. To elucidate the molecular mechanism of this synergy, we investigated the effects of the two drugs, individually and in combination, using a comprehensive approach including two-dimensional differential in-gel electrophoresis (2D DIGE).

2020-05-26 | PXD013725 | Pride

Synergy between PPARgamma ligands and platinum-based drugs in cancer

Project description:PPARγ is a member of the nuclear receptor family for which agonist ligands have anti-growth effects. However, clinical studies using PPARγ ligands as a monotherapy failed to show a beneficial effect. Here we have studied the effects of PPARγ activation with chemotherapeutic agents in current use for specific cancers. We observed a striking synergy between rosiglitazone and platinum-based drugs in several different cancers both in vitro and using transplantable and chemically induced “spontaneous” tumor models. The effect appears to be due in part to PPARγ-mediated downregulation of metallothioneins, proteins that have been shown to be involved in resistance to platinum-based therapy. These data strongly suggest combining PPARγ agonists and platinum-based drugs for the treatment of certain human cancers Keywords: Gene expression, change, synergy of interaction

2007-04-19 | GSE7035 | GEO

Dissecting the Mechanisms of Transcriptional Synergy in Response to Proinflammatory Cytokines in Endothelial Cells

Project description:Dissecting the Mechanisms of Transcriptional Synergy in Response to Proinflammatory Cytokines in Endothelial Cells

| PRJNA971164 | ENA

Molecular mechanisms in Murine Syngeneic Leukemia Stem Cells

Project description:Molecular mechanisms in Murine Syngeneic Leukemia Stem Cells

| PRJNA911837 | ENA